{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T18:30:04Z","timestamp":1787941804373,"version":"build-2784847793"},"reference-count":21,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2014,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>We studied whether the Etest can be used as an alternative to agar dilution to determine antimicrobial susceptibilities of ceftriaxone, cefixime, and cefpodoxime in<jats:named-content content-type=\"genus-species\">Neisseria gonorrhoeae<\/jats:named-content>surveillance. One hundred fifteen clinical and laboratory isolates of<jats:named-content content-type=\"genus-species\">N. gonorrhoeae<\/jats:named-content>were tested following the Clinical Laboratory Improvement Amendments (CLIA)-approved CLSI standard agar dilution method and, separately, by the Etest according to the manufacturer's recommendations. The MICs were determined and compared. Ten laboratory-generated mutants were used to simulate substantially nonsusceptible specimens. The Etest and agar dilution methods were well correlated. Statistical tests produced regression<jats:italic>R<\/jats:italic><jats:sup>2<\/jats:sup>values of 88%, 82%, and 85% and Pearson correlation coefficients of 92%, 91%, and 92% for ceftriaxone, cefixime, and cefpodoxime, respectively. When paired comparisons were made, the two tests were 88.7%, 80%, and 87% within 1 log<jats:sub>2<\/jats:sub>dilution from each other for ceftriaxone, cefixime, and cefpodoxime, respectively. The within-2-log<jats:sub>2<\/jats:sub>agreements were 99.1%, 98.3%, and 94.8% for ceftriaxone, cefixime, and cefpodoxime, respectively. Notwithstanding the good correlations and the within-2-log<jats:sub>2<\/jats:sub>general agreement, the Etest results produced slightly lower MICs than the agar dilution results. In conclusion, we found that the Etest can be effectively used as an alternative to agar dilution testing to determine the susceptibility of<jats:named-content content-type=\"genus-species\">N. gonorrhoeae<\/jats:named-content>to ceftriaxone, cefixime, and cefpodoxime, although we recommend further research into extremely resistant isolates. For isolates within the typical range of clinical MICs, reexamination of the Etest interpretation of susceptible and nonsusceptible categories would likely allow for successful transition from agar dilution to the Etest.<\/jats:p>","DOI":"10.1128\/jcm.02131-13","type":"journal-article","created":{"date-parts":[[2014,2,20]],"date-time":"2014-02-20T05:29:39Z","timestamp":1392874179000},"page":"1435-1440","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":59,"title":["Assessment of Etest as an Alternative to Agar Dilution for Antimicrobial Susceptibility Testing of Neisseria gonorrhoeae"],"prefix":"10.1128","volume":"52","author":[{"given":"Hsi","family":"Liu","sequence":"first","affiliation":[{"name":"Division of Sexually Transmitted Disease Prevention, National Center for HIV\/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Thomas H.","family":"Taylor","sequence":"additional","affiliation":[{"name":"Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Pettus","sequence":"additional","affiliation":[{"name":"Division of Sexually Transmitted Disease Prevention, National Center for HIV\/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Trees","sequence":"additional","affiliation":[{"name":"Division of Sexually Transmitted Disease Prevention, National Center for HIV\/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198707303170504"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656560902731993"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1586\/eri.09.63"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.2807\/ese.15.47.19721-en"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-198810000-00006"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-148-8-200804150-00005"},{"key":"e_1_3_2_8_2","first-page":"332","article-title":"Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infection","volume":"56","author":"Centers for Disease Control and Prevention","year":"2007","unstructured":"Centers for Disease Control and Prevention. 2007. Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infection. MMWR Morb. Mortal. Wkly. Rep. 56:332\u2013336. http:\/\/www.cdc.gov\/mmwr\/pdf\/wk\/mm5614.pdf.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_9_2","first-page":"873","article-title":"Cephalosporin susceptibility among Neisseria gonorrhoeae isolates\u2014United States, 2000-2010","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","unstructured":"Centers for Disease Control and Prevention. 2011. Cephalosporin susceptibility among Neisseria gonorrhoeae isolates\u2014United States, 2000-2010. MMWR Morb. Mortal. Wkly. Rep. 60:873\u2013877. http:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm6026a2.htm.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq289"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-002-0204-8"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.3201\/eid1308.060948","article-title":"Threat to cefixime treatment of gonorrhea","volume":"13","author":"Yokoi S","year":"2007","unstructured":"YokoiSDeguchiTOzawaTYasudaMItoSKubotaYTamakiMMaedaS. 2007. Threat to cefixime treatment of gonorrhea. Emerg. Infect. Dis. 13:1275\u20131277. http:\/\/wwwnc.cdc.gov\/eid\/article\/13\/8\/06-0948_article.htm.","journal-title":"Emerg. Infect. Dis."},{"key":"e_1_3_2_13_2","unstructured":"Centers for Disease Control and Prevention. 9 January 2013. Gonococcal Isolate Surveillance Project. http:\/\/www.cdc.gov\/std\/gisp\/."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.29.3.533-538.1991"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.29.10.2197-2203.1991"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.34.12.3214-3217.1996"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-000969"},{"key":"e_1_3_2_18_2","volume-title":"Methods for antimicrobial susceptibility testing of anaerobic bacteria: approved standard-8th ed.","author":"Clinical and Laboratory Standards Institute","year":"2012","unstructured":"Clinical and Laboratory Standards Institute. 2012. Methods for antimicrobial susceptibility testing of anaerobic bacteria: approved standard-8th ed. CLSI document, Approved Standard M11-A8. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_19_2","volume-title":"Performance standards for antimicrobial susceptibility testing: twenty-third informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2014","unstructured":"Clinical and Laboratory Standards Institute. 2014. Performance standards for antimicrobial susceptibility testing: twenty-third informational supplement. CLSI document, Approved Standard M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_20_2","unstructured":"Centers for Disease Control and Prevention. February 2005. B-88: Neisseria gonorrhoeae reference strains for antimicrobial susceptibility testing. http:\/\/www.cdc.gov\/std\/Gonorrhea\/arg\/B88-Feb-2005.pdf."},{"key":"e_1_3_2_21_2","first-page":"590","article-title":"Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2010: Oral cephalosporins no longer a recommended treatment for gonococcal infections","volume":"61","author":"Centers for Disease Control and Prevention","year":"2012","unstructured":"Centers for Disease Control and Prevention 2012. Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2010: Oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb. Mortal. Wkly. Rep. 61:590\u2013594. http:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm6131a3.htm.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2009.07.008"}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.02131-13","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.02131-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T22:03:09Z","timestamp":1746136989000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JCM.02131-13"}},"subtitle":[],"editor":[{"given":"E.","family":"Munson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["10.1128\/JCM.02131-13"],"URL":"https:\/\/doi.org\/10.1128\/jcm.02131-13","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"2013-08-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-02-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-04-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}